Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.75 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.75 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.75 |
| ▸ | IL2 | P60568 | 10/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155798 | 0.92 | STIM1 (0.75) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL12156023 | 0.91 | STIM1 (0.77) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL12241462 | 0.91 | STIM1 (0.77) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL1702092 | 0.87 | STIM1 (0.67) | STIM1ORAI1ORAI2IL2NPC1 | |
| Zegocractin SCHEMBL18038390 | 0.86 | STIM1 (1.00) | STIM1ORAI1ORAI2IL2 | |
| Zegocractin SCHEMBL29362538 | 0.86 | STIM1 (1.00) | STIM1ORAI1ORAI2IL2 | |
| Zegocractin SCHEMBL29391484 | 0.86 | STIM1 (1.00) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL12155807 | 0.85 | STIM1 (0.73) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL1702130 | 0.85 | STIM1 (0.73) | STIM1ORAI1ORAI2IL2NPC1 | |
| SCHEMBL12155799 | 0.85 | STIM1 (0.69) | STIM1ORAI1ORAI2IL2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-11-12 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.